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DECISION
Subject: Memorandum of Understanding for the implementation of the COST Action
“Advanced Engineering and Research of aeroGels for Environment and Life
Sciences” (AERoGELS) CA18125
The COST Member Countries and/or the COST Cooperating State will find attached the Memorandum of
Understanding for the COST Action Advanced Engineering and Research of aeroGels for Environment and
Life Sciences approved by the Committee of Senior Officials through written procedure on 13 November
2018.
MEMORANDUM OF UNDERSTANDING
For the implementation of a COST Action designated as
COST Action CA18125
ADVANCED ENGINEERING AND RESEARCH OF AEROGELS FOR ENVIRONMENT AND LIFE
SCIENCES (AERoGELS)
The COST Member Countries and/or the COST Cooperating State, accepting the present Memorandum of
Understanding (MoU) wish to undertake joint activities of mutual interest and declare their common
intention to participate in the COST Action (the Action), referred to above and described in the Technical
Annex of this MoU.
The Action will be carried out in accordance with the set of COST Implementation Rules approved by the
Committee of Senior Officials (CSO), or any new document amending or replacing them:
a.  “Rules for Participation in and Implementation of COST Activities” (COST 132/14 REV2);
b.  “COST Action Proposal Submission, Evaluation, Selection and Approval” (COST 133/14 REV);
c.  “COST Action Management, Monitoring and Final Assessment” (COST 134/14 REV2);
d.  “COST International Cooperation and Specific Organisations Participation” (COST 135/14 REV).
The main aim and objective of the Action is to boost the development of aerogel-based products for
biomedical and environmental applications by setting up a multidisciplinary knowledge-based network to
facilitate the exchange of ideas, expertise and outcomes by encompassing European-key actors in this field
from technological, scientific and market perspectives.. This will be achieved through the specific objectives
detailed in the Technical Annex.
The economic dimension of the activities carried out under the Action has been estimated, on the basis of
information available during the planning of the Action, at EUR 72 million in 2018.
The MoU will enter into force once at least seven (7) COST Member Countries and/or COST Cooperating
State have accepted it, and the corresponding Management Committee Members have been appointed, as
described in the CSO Decision COST 134/14 REV2.
The COST Action will start from the date of the first Management Committee meeting and shall be
implemented for a period of four (4) years, unless an extension is approved by the CSO following the





AERoGELS COST Action intends to bring together the knowledge on research and technology of aerogels at
the European level from academia, industry and regulatory experts. Aerogels are a special class of
mesoporous materials with very high porosity and tunable physicochemical properties. Although some types
of aerogels have already reached the market in construction materials and aerospace engineering, the full
potential of aerogels are still to be assessed for other sectors. In this Action, the use of aerogels specifically
for environmental and life sciences applications will be explored in a multidisciplinary approach to tackle two
of the current main European challenges: circular economy and active ageing. The scope of the Action is to
advance the state-of-the art on the topic by joining the knowledge and efforts of the most renowned experts
on cutting-edge aerogel technology, on advanced characterization of materials as well as on biomedical and
environmental research. Aerogels will be assessed from a materials performance point of view but also
regarding health and environmental implications. AERoGELS Action will set a forum to disseminate
knowledge to society, to boost the industry-academia interactions and to train European young researchers
on research, innovation and entrepreneurial skills via technical schools, publications and STSM exchanges.
Finally, the interdisciplinary collaborations are expected to yield innovative and integrated solutions for
environment and for life sciences. The long-term scope of this Action is to develop an aerogel technology
able to improve the welfare of European people and to move towards cleaner and smarter production in
Europe.
Areas of Expertise Relevant for the Action
● Materials engineering: New materials: oxides, alloys,
composite, organic-inorganic hybrid
● Medical engineering: Medical engineering and technology
● Chemical engineering: Chemical engineering: processes
and products (others)
● Nano-technology: Nano-materials and nano-structures









To achieve the main objective described in this MoU, the following specific objectives shall be
accomplished:
Research Coordination
● To establish clusters within the COST consortium with academia and companies that will early define the
specific cutting-edge bioactive aerogels to be developed, considering their market impact.
● To establish clusters between COST-members from academia and companies that will early define the
specific innovative aerogel features and products to be developed for environmental applications,
considering their market impact.
● To explore novel or modify existing chemical (sol-gel) and physical (e.g., drying) routes for aerogel
processing, and to develop and adapt analytical tools for aerogel characterization and performance.
● To evaluate innovative aerogel processing approaches to turn advanced materials development from lab-
scale into commercial products from technological, safety and economical points of view.
● To set the basis of a common knowledge on aerogels regarding toxicity, health, risk safety assessment,
environmental impact and regulatory issues.
Capacity Building
● To identify the opportunities of aerogel technology to give response to the current European demands in
the fields of biomedicine and environmental application.
● To set up a network or community on aerogel technology in a lifelong basis going beyond the timeframe
of the COST Action by facilitating the joint application in consortia to open project calls from
3
European/international funding programmes.
● To assemble trans-disciplinary expertise on nanostructured materials from different domains (industry,
academia, regulatory experts) and disciplines (raw material suppliers, technology developers, R&amp;D,
manufacturers).
● To join together research efforts, best working practices, expertise and facilities from the Action members
to reach the main aim of the Action.
● To train early stage researchers and students for skills development with courses and exchange activities
to become the next-generation scientific and technological leaders.
● To promote, disseminate and share knowledge on aerogel technology to academia, industry and society
through different media (scientific articles, books, patents, leaflets, web page, participation in congresses
and exhibition fairs, Master and PhD Thesis, mass media).
















1. S&T EXCELLENCE 
1.1. CHALLENGE  
1.1.1. DESCRIPTION OF THE CHALLENGE (MAIN AIM) 
Aerogels are unique nanostructured porous materials containing >90 vol% air and entitled with special 
properties (Fig. 1) of utmost interest for certain advanced applications1. However, biomedical and 
environmental applications are two emerging market opportunities in Europe that are still unexploited 
for aerogels up to now and will be explored within this Action. AERoGELS Action aims to fill this gap. 
 
Fig. 1. Advanced biomedical and environment applications to be prospected in AERoGELS Action 
 
Current challenges in biomedicine are interlinked to the new socio-sanitary needs in Europe and 
worldwide derived from the dramatic demographic changes and new population lifestyle taking place2. 
Namely, European population is experiencing an outstanding increase in longevity with 18.5% people 
above 65 years already in 2014 and a prospect of 29.5% by 2060. New materials and approaches 
should provide solutions to enhance the quality of life and well-being at least at the same pace as the 
population ages and the prevalence of chronic diseases (cancer, cardiovascular, diabetes) rises. 
However, the lack of sufficient interdisciplinary collaboration between academia and industry and 
between different scientific domains results in a fragmented knowledge severely jeopardizing the 
development of the next-generation medicines and grafts able to respond to the new social demands.  
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For environmental applications, a change towards circular economy, a more sustainable management 
of resources, is one of the main pillars to be addressed by Europe in the current context of ever-
increasing energy (50% more by 2030) and water (40%) demands3-5. This new environmental model is 
crucial to tackle the climate change and to avoid potential risks of water and food shortages. This new 
paradigm goes beyond environmental concerns and is part of a structural change in the European 
economy to mitigate external dependence and to maximize competitiveness to reach a prolonged 
prosperity of the continent. The collaboration in research between all the actors from the value chain 
as well as a suitable interaction with regulatory experts on circular economy are needed to promote 
this new environmental context and to reach the defined milestones with success and on time. 
Overall, current research efforts on nanostructured materials for biomedical and environmental 
applications have severe limitations in terms of yield, reproducibility and toxicity6-8. These pitfalls 
translate into cumbersome processing techniques and limited cost-efficiency that restricts the access 
to the market. Novel advanced nanostructured materials, particularly aerogel-based materials, are 
susceptible of contributing to reach the mentioned challenges circumventing the said limitations9-10. 
The main aim of AERoGELS Action is to boost the development of aerogel-based products for 
biomedical and environmental applications by setting up a multidisciplinary knowledge-based network 
to facilitate the exchange of ideas, expertise and outcomes by encompassing European key actors in 
this field from technological, scientific and market points of view. The Action will bring together key 
actors from academia and industry from materials science, chemical engineering, biology, 
environmental chemistry, pharmaceutical technology, physics, pharmacology, regenerative medicine 
and toxicology domains as well as regulatory experts and innovation managers to boost together the 
development and applications of aerogels as high added value products. The obtained advanced 
materials will be used in biomedical and environmental applications for several potential sectors as 
beneficiaries and, particularly, the general society (Fig. 1). Many of the aerogels within this Action will 
be processed from renewable resources (polysaccharides and proteins) thus participating to the 
sustainable bio-economy approach by obtaining specialty products from commodity polymers. 
1.1.2. RELEVANCE AND TIMELINESS 
Aerogel-based products can actively contribute to solve the current unveiled challenges in biomedicine 
and environmental remediation, where novel formulations and innovative nanostructured materials are 
explored to render products with predictable morphologies and a precise control of their properties. 
Namely, novel aerogel-based formulations retaining components previously approved by regulatory 
agencies are of particular interest for biomedical applications from regulatory and economical 
perspectives. Advanced carriers are under research in pharmaceutical technology to tackle current 
limitations in the formulation of proteins, cytotoxic drugs and low-water soluble drugs regarding 
stability enhancement, side effects minimization and therapeutic effect. In regenerative medicine, 
novel synthetic nanostructured scaffolds are being prospected to overcome the problems of availability 
(>2·106 procedures per year worldwide for bone grafting), slow recovery, infections and unwanted 
responses occurring with biological grafts, the gold standard. For wound healing, the use of aerogels 
in medical devices allows the gelation only into the lesion and keeps a proper exudate equilibrium at 
the wound, avoiding the traumatic removal from perilesional skin of conventional products. 
For environmental applications, Europe seeks innovations regarding low carbon emissions processes 
as well as air and water treatments to prevent health and environmental risks arising from pollutants 
(greenhouse gases, nanoparticles carried by flue gas, carcinogenic compounds, endocrine disruptors, 
heavy metals, sabotage agents or medicines with additive effects) in humans, biota and environment. 
These new solutions for pollutants should embrace all the steps of the circular economy model: 
process innovations to mitigate emissions, novel analytical tools allowing faster detection and at lower 
concentrations, and the development of prompt and highly efficient remediation techniques. 
Despite the unique properties of aerogel-based materials having urged the emergence of novel 
commercial solutions in several fields (thermal insulation, textiles, aerospace engineering), there is still 
a paucity of information regarding the potential application of aerogels for biomedicine (pharmaceutical 
technology, regenerative medicine, wound healing) and environmental solutions (sound insulation, air 
cleaning, water pollutant treatment), where no aerogel-based product has reached the market yet. The 
state-of-the-art for these fields is mainly precluded to aerogel research from engineering and materials 
science points of view and where intersectorial collaborations are still scarce. The relevance of the 
topic can be ascertained by recent review articles9-17 and two on-going editorial projects: the second 
edition of the Aerogels Handbook1, and other book fully devoted to bio-based aerogels18. AERoGELS 
Action provides the ideal set-up to assemble European expertise to evaluate the potential of aerogels 
as advanced materials intended for biomedical and environmental applications. This collaborative 
initiative will set a scientific and technological platform to generate added value solutions in terms of 
scientific knowledge, high-performance materials, and efficient, health-compliant and environmentally 
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responsible technologies. Finally, AERoGELS Action will set the basis of future international 
collaborations, notably as joint-research projects within the Horizon 2020 (H2020) and subsequent 
Programmes. 
The timeliness to implement this Action is ideal since the concepts of active ageing and circular 
economy are looking for novel advanced materials and approaches for biomedical and environmental 
applications, respectively. This technological prospective is validated by the myriad of H2020 calls 
fitting the scope of this Action, and by the forthcoming European social (ageing of population) and 
economic (circular economy, added-value innovative products and energy-efficient solutions against 
foreign low-cost alternatives) paradigms. For environmental applications, there is a major concern in 
the protection of resources (Water JPI) and in the valorisation of wastes and by-products using 
biorefinery approaches (BioBased Industries PPP). In biomedical applications, there is a specific 
H2020 R&I Challenge (Health, Demographic Changes and Welfare) and other European calls (EIT 
Health, KIC in Active Ageing, InfectERA) seeking high-performance, reliable, safe and reproducible 
products to give response to the current European demographic scenario of longevity by extending 
their lifetime efficiency and a more effective and responsible use of drugs (e.g., antimicrobials).  
1.2. OBJECTIVES  
1.2.1. RESEARCH COORDINATION OBJECTIVES 
This Action will assemble the diverse expertise from the participants in different Working Groups (WG) 
to accomplish the main aim of evaluating aerogels as advanced materials for biomedicine and 
environment from scientific, technological and market-oriented perspectives. The initial consortium 
encompasses the expertise needed to reach this objective and is expected to act as pole of attraction 
for other relevant and emerging researchers linked to the topic of the Action. The cooperation between 
the AERoGELS COST-members is essential to effectively tackle the research coordination objectives 
of the Action (see metrics for their monitoring in the table below): 
i.1. To establish clusters within the COST consortium with academia and companies that will early 
define the specific cutting-edge bioactive aerogels to be developed, considering their market impact. 
i.2. To establish clusters between COST-members from academia and companies that will early 
define the specific innovative aerogel features and products to be developed for environmental 
applications, considering their market impact. 
i.3. To explore novel or modify existing chemical (sol-gel) and physical (e.g., drying) routes for aerogel 
processing, and to develop and adapt analytical tools for aerogel characterization and performance. 
i.4. To evaluate innovative aerogel processing approaches to turn advanced materials development 
from lab-scale into commercial products from technological, safety and economical points of view. 
i.5. To set the basis of a common knowledge on aerogels regarding toxicity, health, risk safety 
assessment, environmental impact and regulatory issues. 
Objective indicator Metrics 
i.1 Scientific contributions‡ on aerogels for biomedical applications 35 
i.2 Scientific contributions‡ on aerogels for environment applications 35 
i.3 Scientific contributions‡ on aerogel synthetic routes and characterization tools 30 
i.4 Number of academia-industry collaborations (STSM, joint project applications, 
industrial participation in events) 30 
i.5 Number of external documents on health risk assessment 25 
‡ Peer-review papers, proceedings and patents 
1.2.2. CAPACITY-BUILDING OBJECTIVES 
This Action will merge fundamental and applied research to build up a robust interdisciplinary scientific 
cooperation with the common scope of developing materials, technologies and protocols able to 
advance on the state-of-the-art of aerogels for environment and life sciences applications. AERoGELS 
Action will encompass theoretical and experimental knowledge on the topic joining forces to carry out 
the challenge of getting precise materials design, reproducible processes and society-demanding 
solutions. The creation of technology-based start-ups and spin-offs will be a logical outcome of this 
Action. All the actors from the value chain (raw material suppliers, researchers, technology providers, 
manufacturers and regulatory experts) will be integrated to achieve these complex tasks. Overall, the 
cooperation between the AERoGELS members is essential to effectively tackle the specific capacity-
building objectives established for this Action: 
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ii.1. To identify the opportunities of aerogel technology to give response to the current European 
demands in the fields of biomedicine and environmental application. 
ii.2. To set up a network or community on aerogel technology in a lifelong basis going beyond the 
timeframe of the COST Action by facilitating the joint application in consortia to open project calls from 
European/international funding programmes.  
ii.3. To assemble trans-disciplinary expertise on nanostructured materials from different domains 
(industry, academia, regulatory experts) and disciplines (raw material suppliers, technology 
developers, R&D, manufacturers). 
ii.4. To join together research efforts, best working practices, expertise and facilities from the Action 
members to reach the main aim of the Action. 
ii.5. To train early stage researchers and students for skills development with courses and exchange 
activities to become the next-generation scientific and technological leaders. 
ii.6. To promote, disseminate and share knowledge on aerogel technology to academia, industry and 
society through different media (scientific articles, books, patents, leaflets, web page, participation in 
congresses and exhibition fairs, Master and PhD Thesis, mass media). 
Objective indicator Metrics Comments 
ii.1 Number of COST events (workshops, 
meetings, training schools, conferences, STSM) 
50 In-house workshops will be organized 
to promote industry participation 
ii.2 Number of applied joint projects by Action 
members 
25 Target application success rate: 30% 
ii.3 Percentage of academia-industry STSM 
exchanges 
10% 11 industrial partners already interested 
in the Action 
ii.4 Number of joint publications from at least 2 
Action members 
30 15 best collaborative work prizes and 
Open Access articles during the Action 
ii.5 Average percentage of ECIs per year involved 
in the Action (members, STSM, event participants) 
60% 39% of the first Action consortium 
members are ECIs 
ii.6 Total number of scientific publications, meeting 
contributions and mass media participations 
300 2 special issues on the Action in peer-
reviewed journals will be edited 
1.3. PROGRESS BEYOND THE STATE-OF-THE-ART AND INNOVATION 
POTENTIAL  
1.3.1. DESCRIPTION OF THE STATE-OF-THE-ART 
Aerogels are a special class of materials able to encompass unique properties like high porosity, light-
weight, outstanding textural properties such as high specific surface area and tunable surface 
chemistry1. Namely, the low density and the high porosity in the mesoporous range of aerogels have 
been notably exploited for thermal insulation in building materials and aerospace technology. Several 
products are already commercialized for these specific applications (e.g., insulating pipes/boards/ 
blankets/translucent panels). Aerogel source has been traditionally precluded to synthetic organic 
polymers (e.g., resorcinol-formaldehyde, polyurethane) and inorganic oxides (typically silica). 
Nevertheless, natural biopolymers (polysaccharides, proteins) and hybrid materials have been 
recently considered as new aerogel sources with an exponential increase in the publications on bio-
aerogels during the recent years16. Natural biopolymers are of special interest for biomedical 
(biocompatibility and biodegradability) and environmental (renewability) applications12,15. Well-known 
natural polymers (cellulose, starch, pectin) can be transformed into high-added value aerogel-based 
materials. New materials from biopolymers (e.g., nanocellulose) in the form of aerogels also have 
promising biomedical and separation applications among others11. 
From a technological point of view, supercritical fluid-based drying of gels is regarded as the most 
suitable aerogel end-processing approach13. Optimization and integration of the supercritical drying 
process from an economic and environmental perspective as well as alternative drying processes 
have been actively sought. Overall, four main issues on aerogel technology are generally recognised 
as critical and not fully explored yet: (1) To extend the use of aerogels for biomedical and environment 
applications; (2) To develop aerogels with selective response to external stimuli and with smart 
behaviour; (3) To establish robust prediction models and characterization tools for the quality control 
of aerogels; (4) To set manufacturing protocols for the safe and reproducible processing of aerogels. 
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1.3.2. PROGRESS BEYOND THE STATE-OF-THE-ART 
The survey of literature, patents and previous research on aerogels unveils the biomedical and 
environmental applications as two important and prospective directions for the development of 
aerogels. Process and materials engineering, scaling–up as well as toxicity, health, risk assessment 
and regulatory aspects must be taken into account to successfully advance in these directions. These 
points have not been considered in open literature so far and will be addressed in this Action. 
For pharmaceutical applications, this Action aims at compiling the state-of-the-art and extending the 
knowledge on aerogel formulations to obtain better therapeutic outcomes with modified drug release 
profiles, improved recovery times and/or improved acceptance and adherence of the patients. The 
advantages of the use of bio-based aerogels as carriers are improved dissolution rate of poorly water 
soluble drugs, high specific drug loadings, enhanced stability of amorphous drugs and excellent air 
flowability, which are requested for certain administration routes (oral, pulmonary, nasal)12,14-15. To 
reach the Action objectives, partners will develop new formulations and the processing of innovative 
aerogel-containing dosage forms. Smart aerogel formulations showing tuneable stimuli-responsive 
drug release behaviour relevant to the intended administration route/target site, being able to deliver 
cytotoxic drugs (e.g., anti-cancer drugs) with enhanced therapeutic effect, or being compatible with the 
incorporation of proteins and polypeptide-based drugs are among the foreseen progresses to be 
achieved. From the processing point of view, the handling (powder flow properties, stability under 
storage), dosing (tableting), manufacturing (integrity under tableting, shaping of the aerogel 
morphology, choice of packaging) and validation of the aerogel dosage forms for different therapeutic 
applications and administration routes, as well as the implementation of the aerogel processing under 
Good Manufacturing Practices conditions are to be endeavoured within this Action. 
For regenerative medicine and wound healing, important progresses have been attained in the last 
years for aerogel-based scaffolds10, but should still be regarded as an emerging alternative under 
evaluation concerning methods for the processing of nanostructures mimicking natural tissue and with 
biological compatibility tests pending. The progresses to be attained within AERoGELS Action deal 
with the materials design and regulatory compliance. Accordingly, efforts will be devoted, on one 
hand, to get a robust processing method to confer a controlled macroporosity to the aerogels allowing 
host cell colonization, or promoting allo- and xenocells proliferation, to engineer aerogel synthetic 
methods able to improve the mechanical properties of the scaffolds to temporarily surrogate natural 
tissue without compromising the biocompatibility of the material, and to allow the incorporation of 
bioactive compounds (e.g., growth factors) in high yields and with retained activity to promote the 
biological tissue growth19. From a regulatory point of view, the cytocompatibility and sterility of the 
aerogel-based materials should be predicted beforehand by developing precise methodologies able to 
ensure the presence of organic solvents or crosslinkers at concentrations below cytotoxic levels and to 
guarantee sterility assurance level (SAL) 6 sterility conditions for aerogel implants, as needed by 
regulatory agencies. For the specific case of wound healing20, the potential of aerogels as therapeutic 
platforms to promote and accelerate the natural wound healing process through a control of the 
presence of a balanced exudate in the wound surroundings, gas permeability (transpiration) and 
sustained release of bioactive compounds will be explored and compared to the benchmark. 
For environmental applications, this Action will develop aerogels with better performance than the 
current solutions (if any) in the market in terms of reliability, fast response and ease of use, coupled to 
(i) the explorative search of new raw materials and feedstocks, (ii) a processing with a responsible 
management of resources, and/or (iii) a competitive production cost. Accordingly, a critical study of 
aerogel sources coming from the biorefinery approach will be explored for the reuse or valorization of 
wastes (wasted newspaper, waste biomass) and by-products (lignin). Physicochemical modifications 
of current aerogel sources in terms of morphology and chemical functionalities will be actively 
prospected for environmental applications16-17. Namely, aerogel-based products giving improved 
response to the capture and/or degradation of oil spills and various toxic compounds will be developed 
in the form of absorbents, adsorbents or catalysts21-24. The recovery of pollutants with economic 
interest will be also considered in the adopted approaches. Moreover, new sensor solutions for the 
fast detection of air and water pollutants (endocrine disruptors, sabotage agents, metabolites, human 
and veterinary drugs, pesticides) with reduced sampling times and high sensitivities are also an urgent 
environmental concern to be performed within this Action using aerogel-based stationary phases12. 
Finally, promising aerogel solutions will be implemented using rigorous processing designs with full 
integration of utilities to minimize energy consumptions and to reduce and (when applicable) reuse 
raw materials for the sake of process economics and of environmental and health-and-safety issues. 
Concerning risk and regulatory issues, there is a paucity of information regarding the health risk 
assessment and other regulatory aspects on these materials. A “library of knowledge” and protocols 
for the health risk assessment of aerogels will be generated during the Action lifetime. This safety 
regulatory compendium will be crucial to advice on the commercialization possibilities of the different 
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aerogel-based formulations coming out from the collaboration within this Action. In addition, protocols 
with the best practices for handling and processing aerogels will be elaborated to mitigate risks. 
Overall, AERoGELS Action will fulfil the abovementioned objectives and final goals by bringing 
together the joint efforts of scientists from different domains and supported by industry in the frame of 
a defined work plan (Section 3.1) and the transfer of knowledge between academia and industry and 
society by means of a dissemination and exploitation plan (Section 2.2.2). 
1.3.3. INNOVATION IN TACKLING THE CHALLENGE 
The traditional development of aerogels have been carried out by materials scientists and process 
engineers with expertise in the technology, but not necessarily familiar with the knowledge and the 
regulation concerned for the production of aerogels for environmental and, particularly, biomedical 
applications. As an example, conferences on aerogels are mainly taking place as specific workshops 
or as parallel sessions within technological meetings on sol-gel chemistry, process engineering or 
material science. To the best of our knowledge, no specific sessions on aerogels have been organized 
within conferences on biomedicine, regenerative medicine or environmental applications. Additionally, 
no previous COST Action on the development and applications of aerogels has been funded so far. 
The innovation of AERoGELS Action is to tailor aerogel technology to the social demands regarding 
health and environment through the interdisciplinary collaborations between the Action-members. The 
COST Action is accordingly structured in different Working Groups (cf. Section 3.1.1) by 
encompassing aerogel technologists (WG3) with biomedical (WG1: medical doctors, biologists, 
pharmacists, bioengineers), environmental (WG2: gas cleaning, water remediation, biorefinery, 
catalysis), regulatory experts (WG5: attorneys, agencies, associations, NGOs) and other stakeholders 
(WG4: raw material and end product industries, innovation managers, IP-lawyers, NGOs). The 
research activities of each COST-member will be in their core area to guarantee their funding by 
already existing projects, but now enhanced by the cooperation within this COST Action. The activities 
of the Action will be carried out through a translational technology↔application bidirectional 
information flow: for example, technology-based conferences and meetings to be scheduled by this 
Action will be organized as satellite or parallel events of application-based international congresses 
and symposia and vice versa. The training schools will also promote this challenge by assembling 
experts and early career researchers (ECIs) from both domains to train the future first-generation 
of research leaders on aerogel-oriented biomedical and environmental applications. Research stays 
(STSM) within the Action will also promote this bidirectional collaboration as well as the academia-
industry exchanges, the latter of utmost importance to turn potential aerogel-based materials 
inventions into innovations able to reach the biomedical and environmental markets. The 
involvement of industrial members of the COST Action and regulatory experts will be also 
promoted through in-house workshops and preferential invitations as lecturers in COST events. 
Finally, selected academic partners (at least from five different European countries) will incorporate 
the topic of aerogels as a subject itself or as a module in MSc or PhD studies from both technological 
and biomedical/environmental disciplines before the end of the Action lifetime as a long-term 
“legate” of the Action objectives to ensure the training of the second and following next-generations 
of aerogel-oriented biomedical and environmental experts to lead future innovations in these fields. 
1.4. ADDED VALUE OF NETWORKING  
1.4.1. IN RELATION TO THE CHALLENGE 
Active ageing and circular economy are current mainstream challenges in Europe4,25: the EU devoted 
the European Year 2012 to promote active ageing as a basis for solidarity between generations and 
currently there are several active R&I research programmes on this topic; in September 2016 the EU 
endorsed the Paris agreement towards more energetic efficient and low carbon economy and the 
2030 climate and energy framework sets the roadmap for the next decade. The design and 
engineering of aerogels with special properties can shed light to tackle the current biomedical 
concerns and to give priority to energetic efficiency. However, the main challenge in the development 
of aerogel-based solutions for these fields is the fragmentation between the technology and 
application, coupled to an academia-industry-national agencies interlinking to be improved. As a 
result, there are no aerogel-based products in the market for biomedical and environment applications 
so far, in spite of their high potential. A novel paradigm with a suitable alignment between 
technological developments on aerogels and the design needs for the intended application through a 
jointly, multidisciplinary and multisectorial approach is crucial to reach research excellence and to 
boost the technological progresses on the topic. 
 
        11 
AERoGELS Action will assemble renowned European and international experts from different 
disciplines (chemical process engineering, biological sciences, materials science, environmental 
chemistry, drug delivery, regenerative medicine, pharmaceutical technology, national agencies, 
physics, pharmacology, toxicology) to look for a more effective technological approach in the 
development of aerogels if compared to the previous fragmented and sporadic ones. The activities to 
be implemented during this Action will boost these advances on applied aerogel technology to reach 
the leadership of Europe and affiliated COST countries on the topic. 
1.4.2. IN RELATION TO EXISTING EFFORTS AT EUROPEAN AND/OR INTERNATIONAL LEVEL 
The aims and scope of this COST Action are exclusive and not replicated in active calls in the COST, 
ERA, EIT, IMI, or H2020 R&I programmes. Nevertheless, the Action is aligned with the Active Ageing 
and Circular Economy concepts, which are parts of the roadmaps of the European Commission and 
National Programmes for the forthcoming years and decades. Therefore, this Action will strengthen 
current European research projects providing them with a more interdisciplinary dimension, and will 
also act as a seed for the set of new consortia for the preparation of collaborative research proposals. 
AERoGELS Action has no overlap with previous COST Actions but interesting complementarities. 
Certain COST Actions (MP1301, CA15114, MP1404, CA16205, CA16202, TD1407, CA17136) have 
been devoted to different specific biomedical (inhalation, oral administration, regenerative medicine, 
infectious diseases) and environmental (air pollution, human health threats) applications. To broaden 
the scope, audience and impact of AERoGELS Action, the Management Committee (MC) will look for 
liaisons and synergies with these Actions by i) learning from results of already closed Actions, ii) 
contacting the MCs of the active COST Actions for the organization of joint events, and iii) prospecting 
their Action members for hosting scientific missions and for being speakers in AERoGELS-events. 
 
2. IMPACT 
2.1. EXPECTED IMPACT  
2.1.1. SHORT-TERM AND LONG-TERM SCIENTIFIC, TECHNOLOGICAL, AND/OR 
SOCIOECONOMIC IMPACTS 
AERoGELS Action endeavours the search for materials innovations on aerogels for biomedical and 
environment applications, two unmet fields for these materials so far. This Action will represent in the 
short-term a highly needed collaborative network for scientific-technological advances by matching 
knowledge and expertise on the best processing practices on aerogel technology and on the materials 
performance taking into account the required specifications and regulatory aspects for the intended 
application. The networking and knowledge exchange efforts undertaken during this Action will set the 
basis of forthcoming scientific-technological joint collaborations and the filing of patents leading to 
ground-breaking product developments reaching the market in a mid-long term. The exploitation of the 
scientific-technological results will be carried out by potential “spin-off” companies resulting from the 
Action, by the industrial Action members or by license agreements with other existing companies. 
From a socioeconomic point of view, AERoGELS Action has an upside potential in biomedical and 
environmental applications with the development of advanced technologies and products based on the 
use of aerogels. For biomedical applications, better clinical outcomes resulting in reduced recovery 
time periods and the subsequent savings in direct (hospitalization) and indirect (sick leave and in-
home healthcare expenses) costs of the treatments are the expected results from the use of aerogels 
in a global context of aging population as primary social driver to burgeon healthcare expenses. For 
pharmaceutical technology, the novel formulations to be herein endeavoured will likely increase the 
therapeutic efficiency of the treatment (improved lung deposition by oral inhalation, improved 
dissolution rate of poorly water-soluble drugs in oral drug delivery, enhanced drug permeation in nasal 
delivery) leading to economic savings and higher social adherence2,8. For regenerative medicine, cost-
effective and safe aerogel materials aim to give response to the availability problems and deficient 
tissue recovery of current grafts. The global market only for bone implants is of ca. 5,000 M€/yr25-26. 
For wound healing, the target is to develop advanced dressings able to prevent or to heal chronic 
wounds such as diabetic foot ulcers (15% incidence among diabetic patients and main cause of non-
traumatic amputation of the lower extremity) or pressure ulcers (representing ca. 4% of total national 
sanitary costs)20. This use of aerogels aims to become a high growth technology for the market of 
advanced bioactive dressings representing ca. 500 M€/yr worldwide and a top growth segment 
 
        12 
(expected annual growth: 15-25%)27. For environmental applications, the reduction of water and air 
pollution, energy savings, responsible use of resources and fast detection of pollutants are expected 
results from the Action activities. New cheaper and/or more effective materials will be suggested for 
water treatment and air/gas stream cleaning. This Action will thus contribute to the reinvention of the 
European economy towards process innovations following the circular model of efficient and 
responsible management of resources and low carbon emissions estimated at 2.7 trillion €28-29. 
2.2. MEASURES TO MAXIMISE IMPACT 
2.2.1. PLAN FOR INVOLVING THE MOST RELEVANT STAKEHOLDERS  
The transdisciplinary context and capacity-building objectives of this Action coupled to its expected 
high socioeconomic impact results in a wide societal range to be involved as stakeholders: 
• Public research institutions: universities and research institutes will be the major group of the Action. 
PhD students and young postdoctoral scientists will be involved with specific activities (ECI’s Forum, 
STSM) and training schools on scientific and transversal skills. Tenure-track professors will be 
involved as invited speakers in training schools and scientific events and will participate in academia-
industry collaborations to boost the valorisation of results. 
• Industry: the involvement of profit-driven companies as raw material suppliers for aerogels, 
technology suppliers or end-user biomedical and environmental products will be actively promoted 
within the Action. A high share of participation of these stakeholders, with special attention to SMEs, 
will be promoted with in-house technological events and specific quotas (ca. 10%) for the participation 
in STSM and scientific events. A “Forum of Emergence” will be also organized (Section 2.2.2). 
• Clinical practitioners and patient organizations will be regularly updated with news (Section 2.2.2) on 
the Action progresses for the biomedical application-driven aerogels to avoid misinterpretations of the 
materials use and to promote the translation to clinical trials. They will be also invited to participate as 
speakers in training schools or as attendants in biomedical-oriented COST scientific events. 
• Regulatory agencies, NGOs and environmental organizations will be invited to participate in this 
Action and the MC will have a fluid communication to ensure the alignment of the application-driven 
aerogels with the European legislation (e.g., health and safety issues, European Medicines Agency-
guidelines). 
• General society will be the major beneficiary of the scientific outcomes of the Action. The results of 
the Action will be European researchers trained with advanced skills and the development of 
advanced technological solutions that translate into higher employability, economic competitivity and 
welfare state in Europe. A dissemination plan for the general public is foreseen (Section 2.2.2). 
2.2.2. DISSEMINATION AND/OR EXPLOITATION PLAN  
The relevance and timeliness of the scope of this Action urge the implementation of a dissemination 
and exploitation plan able to reach the broadest of the audiences (cf. Section 2.2.1). The key message 
of the Action will be adapted to each specific audience for a more efficient communication. Different 
activities will be carried out: 1) to share the technological and scientific outcomes, 2) to discuss and 
exchange different points of view to boost the setup of new research topics and collaborative projects, 
3) to increase the impact of the Action on policy makers and 4) to raise awareness of the Action: 
• Workshops, conferences and seminars for COST and non-COST participants to spread results and 
knowledge to the research community and to promote networking for future collaborations.  
• Scientific publications and reviews in high impact factor journals to set research prospects in the 
fields and to disseminate milestones of the Action. Whenever possible, publication in Open Access will 
be financially promoted. A specific website of the COST Action will be set and weekly updated. e-
newsletters (each semester), press releases (on Action impacts and achieved milestones), agenda 
and fact sheets will be publicly accessible. The web will include an Intranet for Action members with 
scientific documents and Action forms. Twitter and Facebook accounts will be also set for the Action. 
• Opinion papers and recommendations will be published to have a high impact and to meet 
consensus among the different stakeholders of the Action. 
• Educational material, videos, press releases, interviews and articles in EU-media, national or 
regional press seeking a large array of audiences will be disseminated in close collaboration with the 
Public Relations and Community Offices of the COST Action-member institutions. 
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• Standard documents will be developed to be proposed to CEN, related to safety protocols when 
handling and processing aerogels, and the best practices for characterization of aerogels. 
• Public lectures and in-house meetings will be organized in every COST Action-country to widen the 
communication with the general society and with key industrial companies, respectively. 
• Regarding intellectual property rights (IPR), the standards from the European Patent Office will set 
the common rules for all the COST Action members and the ownership and inventorship criteria. The 
IPR plan will include i) invited talks in COST events for IPR training; ii) promotion of results protected 
by patents as a dissemination tool and publication in the Action web page; iii) organization of a “Forum 
of Emergence” consisting on business-to-business meetings, elevator pitches and talks between 
academic members and industry to offer networking opportunities, cross-training to professionals, 
feedback from stakeholders and collaborative agreements so that society could benefit from the 
knowledge generated in the Action. 
2.3. POTENTIAL FOR INNOVATION VERSUS RISK LEVEL  
2.3.1. POTENTIAL FOR SCIENTIFIC, TECHNOLOGICAL AND/OR SOCIOECONOMIC 
INNOVATION BREAKTHROUGHS 
In this Action, the use of aerogel technology through an interdisciplinary collaborative approach is 
regarded as a win-win strategy to provide compliant materials designs in terms of yield, reproducibility 
and toxicity to the current social needs in biomedicine and environment. The choice of the proper 
material science-technological approach combination to obtain an advanced material adapted to the 
intended biomedical or environmental application is claimed to give rise to important innovation 
breakthroughs in the field. Although the risk in scientific-technological development is present (Section 
3.1.3), since there are no aerogel-based medical devices or environmental applications in the market, 
the unique expertise assembled in this Action covering the whole value chain can undergo the 
challenge and reach a significant impact. The said impact is linked to the unresolved applications 
(chronic wound healing, cancer, bone scaffolds, sound insulation, air and water pollution monitoring 
and remediation) to be targeted and the subsequent socioeconomic relevance. The risk of feasibility of 
the Action can be considered as relatively low, since many of the desired properties for the end 
materials have been already individually achieved on laboratory scale and will be herein encompassed 
with the support of an interdisciplinary network. The risk of products and technologies not being cost-
competitive for biomedical and environment applications (gross margins>60%) is also low since there 
are aerogel products in markets with lower venture profitability (e.g., building insulation, 20-30%) 30-31. 
There is also a high potential for IP generation through improved product performance with margins in 
order of magnitudes. Moreover, like-for-like substitution of most products with aerogels using the same 
raw materials (polysaccharides, proteins) is possible without significant increase in operating costs, 
and the common solvents (water, alcohol, CO2) used for aerogel processing are already individually 
accepted by agencies thus reducing the associated risks and costs for regulatory compliance. The key 
missing factor is the awareness of aerogels in new market sectors that this Action can address. 
Finally, even in case of failure in application, the vast knowledge generated within the Action will result 
in established protocols and guidelines easily transferred to other applications in the same fields. 
 
3. IMPLEMENTATION 
3.1. DESCRIPTION OF THE WORK PLAN 
3.1.1. DESCRIPTION OF WORKING GROUPS  
AERoGELS Action consists of 5 Working Groups (WGs), which are highly interlinked (Fig. 2) to reach 
the Action objectives.  
As an example, training schools will be organized by a specific WG but all COST-members can 
participate to boost cross-fertilization between WGs. 
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Fig. 2. PERT chart of AERoGELS Action: WG-descriptors, WG-interrelations and expected outcomes 
 
WG1. Pharmaceutical and biomedical applications of aerogels 
Objective – To design and develop aerogel-based products as drug delivery systems for 
pharmaceutical technology, or as medical devices for wound healing and tissue regeneration 
Tasks 
• Development of new therapeutic platforms based on aerogel particulate systems able to significantly 
improve the drug bioavailability and to control the delivery of bioactive molecules 
• Formulation of aerogel beads and scaffolds able to gel in presence of wound exudate enabling the 
treatment of chronic wounds and able to maximize the effect of encapsulated APIs 
• Processing of biodegradable aerogel-containing scaffolds for regenerative medicine with suitable 
morphological, mechanical and biological properties for bone repair able to maximize osteointegration 
Activities 
• To develop aerogel-based medical devices and carrier formulations loaded with biomolecules (poorly 
water soluble drugs, cytotoxic drugs, proteins) and with new administration strategies. Aerogels will be 
designed to amorphize drugs (e.g. adsorptive precipitation) and to modulate the release profile 
depending on formulation composition and manufacturing technique (e.g. smart release and multiple 
release of different biomolecules). These properties will be validated by defining the carrier material 
and the carrier-biomolecules interactions with the dynamic physiopathological environment 
• To characterize the textural properties of aerogel particles and scaffolds as well as specific 
properties for wound healing treatments (gelation properties, exudate absorption, transpiration) and 
bone repair (cell infiltration and colonization capacity, 3D-modelling, sterility, tissue integration) 
• To develop specific, efficient and validated analytical methods and protocols to predict and to assess 
the loading and the (in vitro and in vivo) release profiles of biomolecules from different formulations 
Milestones  
• M1.1: Analytical methods and protocols compendia on aerogel-based pharmaceutical products and 
medical devices for wound healing and bone repair (month 24) 
• M1.2: Knowledge on optimization of manufacturing processes for the production of aerogel based 
pharmaceutical and medical devices with proper physicochemical and biological properties (month 42) 
List of major deliverables 
• D1: STSM to groups in WG5 and joint publications on chemical, physical and microbiological stability 
and health risk assessment on aerogel-based materials for biomedical applications (month 30) 
• D2: STSM to groups in WG4, joint publications, conference and training school on aerogel 
processing technologies for pharmaceutical and biomedical applications (month 33) 
• D3: STSM to groups in WG3, joint publications and review paper on analytical and biological 
protocols used to predict and to assess materials performances (physicochemical and biological 
properties) as well as biomolecules and formulations in vitro and in vivo activities (month 42) 
• D4: Review and workshop on aerogel-based pharmaceutical and biomedical products (month 45) 
 
WG2. Environmental applications of aerogels 
Objective – To design and develop new functional aerogel-based products for sound insulation, 
targeted absorbents and adsorbents, catalysts and sensors, as well as to explore the reuse and 
valorisation of by-products in aerogels through the biorefinery approach 
Tasks 
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• Formulation of aerogels as adsorbents and absorbents for air cleaning, water pollutant treatment and 
detection of contaminants 
• Design of high-performance aerogels as matrices for catalysis and for electrochemical applications 
• Development of bio-aerogels via biorefinery approach and from waste bio-products 
Activities 
• To explore the use of aerogel-based materials for sound insulation as a critical aspect to mitigate 
acoustic contamination in e.g. construction and transport applications 
• To test aerogels “as is” as absorbents/adsorbents of metal ions, or to modify them by post-
functionalization for e.g., selective absorption (oil spillage) or adsorption (VOCs, heavy metals) 
• To develop alternative materials made with templating methods to synthesize aerogels with tuneable 
pore size and surface chemistry as matrices for catalysis, analytical and electrochemical applications 
• To evaluate the use of bio-aerogels, a third generation of aerogels based on polysaccharides and 
proteins, for various applications (acoustic and thermal insulation, absorption, adsorption, catalysis, 
advanced food materials, active packaging). When synthesizing bio-aerogels a special attention will 
be paid on the biorefinery approach which should involve the use of all components which Nature 
provides and waste bio-materials 
Milestones  
• M2.1. Compendia of novel routes for bio-aerogels using biorefinery approaches (month 18) 
• M2.2. Compendia of approaches towards aerogel-based acoustic insulating products (month 24) 
• M2.3. Compendia of functionalization approaches for adsorption/absorption applications (month 30) 
• M2.4. Compendia of materials for catalysis and/or electrochemical applications (month 36) 
List of major deliverables 
• D5: Review on using the bio-refinery approach for the preparation of bio-aerogels (month 18) 
• D6: STSM to groups in WG3 and joint publication on functionalization of aerogels for targeted 
environmental applications (month 30) 
• D7: STSM to groups in WG3&4, joint publications and recommendations on processing pathways for 
the use of aerogels as absorbents and adsorbents (month 36) 
• D8: Review, workshop and training school on aerogels for environmental applications (month 45) 
 
WG3. Materials engineering and characterization 
Objective –For the biomedical and environmental applications, fundamental and applied research will 
be conducted to impart aerogels application-specific properties such as hydrophilicity, lipophilicity, 
ultra-low density, flame retardation, tailored porosity, nanomorphology or surface chemistry 
Tasks 
• Fundamental research on biopolymer self-assembling in solution state, coagulation after anti-solvent 
addition and gel formation. Novel surface modification techniques imparting aerogels specific sorption 
(oil, heavy metals, organic pollutants) and/or capabilities for catalysis/electrochemical applications 
• Development and tailoring of aerogel in the form of particles, beads and scaffolds for biomedical 
(drug delivery systems, medical devices in wound healing, scaffolds for regenerative medicine) and 
environmental (acoustic insulation) applications 
• Development of analytical and in situ tools for modelling the 3D-structure of aerogels and 
measuring/predicting physicochemical and mechanical properties of the resulting materials 
Activities 
• To combine aerogel technology with other processing technologies (e.g., emulsion, plasma 
treatment, supercritical foaming, 3D-printing, jet milling) to get synergies and enhanced properties 
regarding mechanical, physicochemical, microbiological and biological performances 
• To explore materials engineering approaches to get interconnected macropores in aerogels as well 
as mechanical reinforcement strategies to reach the mechanical demands for scaffolds as bone grafts 
• To exploit innovative characterization techniques and modelling tools for the screening of aerogel 
formulations and for the prediction of the materials performance 
Milestones  
• M3.1: Compendia of protocols for manufacturing and post-processing of aerogels (month 15) 
• M3.2: Compilation of synthesis and post-processing of aerogels with tailored properties (month 27) 
• M3.3: Compilation of analytical and modelling tools for characterization of aerogels (month 36) 
List of major deliverables 
• D9: Workshop and training school on aerogels engineering, characterization and modelling (month 
9) 
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• D10: STSM to groups in WG1&2, joint publications and workshop on approaches for processing and 
post-processing of aerogels evaluated for biomedical and environment applications (month 27) 
• D11: STSM between WG3 members and review on analytical tools and modelling approaches for 
the characterization of gels, aerogels and their post-processed counterparts (month 36) 
• D12: External documents on the impact of aerogel processing conditions and post-processing 
modification measures on final properties of the products (month 48) 
 
WG4. Process engineering, development and scale-up for industrial applications 
Objective – To develop process design guidelines for aerogels manufacturing on an industrial scale 
Tasks 
• Development of design procedures for unit operations required to manufacture different types of 
aerogels with various morphologies (monolithic, powder, beads) on an industrial scale, integration of 
unit operations and process optimization for minimizing costs of production 
• Identification of environmental, health and safety issues (handling of aerogels, use of chemicals, 
operation at high pressures, atmospheric emissions, etc.) and develop guidelines to address them 
• Development of guidelines for scaling up from pilot to industrial scale 
Activities 
• To produce various aerogels (inorganic, organic and hybrid) in various forms (powders, beads, 
monolithic blocks) in the laboratory and pilot scales 
• For production of powders and beads, to develop and validate models for predicting parameters 
such as gelation time, droplet size, droplet size distribution, stirring power requirements as a function 
of concentration of reactants, solvents and surfactants. For production of monolithic blocks, to develop 
models for predicting gelation times as a function of reactant concentrations 
• To identify effective unit operations for gel bead separation from gelation baths and develop designs 
• To develop models for prediction of solvent exchange times, determination of solvent composition, 
and determination of processing requirements for supercritical (sc-) drying of aerogels and scale-up 
Milestones  
• M4.1: Compendia of reagents-solvents-other admixtures combinations suitable for manufacturing of 
aerogels with various morphologies and guidelines for process integration (month 24) 
• M4.2: Compilation of models for gelation, solvent exchange and sc-drying, and scale-up (month 36) 
• M4.3: Compendia of effects of process variables on end textural properties of aerogels (month 45) 
List of major deliverables 
• D13: Industry-academia forum on biomedical and environmental applications of aerogels (month 15) 
• D14: STSM in WG3-groups and joint papers on gelation and solvent exchange models (month 33) 
• D15: STSM in groups of WG4 and joint publications on models for supercritical drying and scale-up 
from pilot scale data (month 42) 
• D16: Expert opinion and conference on design aspects for an industrial plant for aerogels production 
for biomedical and environmental applications (month 48) 
 
WG5. Toxicity, health, risk assessment and regulatory aspects 
Objective – To create the framework of health risk assessment of aerogel-based materials for its use 
in specific biomedical and environmental applications 
Tasks 
• Selection of adequate personal protective equipment and indoor air cleaning devices for use during 
aerogels production and handling 
• Health risk and life cycle assessment of aerogels for biomedical applications 
• Health/biota risk and life cycle assessment of aerogels for environmental applications 
Activities 
• To evaluate the associated health, environmental and exposure risks related to aerogel production 
• To perform the specific panel of tests for each biomedical application foreseen for aerogel-based 
compounds (e.g., bacterial/viral load, allergen potential, exposure assessment) 
• To perform the specific panel of tests for aerogels in insulation materials and active surfaces 
Milestones  
• M5.1. Compendia of health and safety procedures for production, handling and transport of aerogels 
• M5.2: Compendia of safety regulatory for environmental application of aerogels-based materials 
identifying at least one health risk category (month 24) 
• M5.3: Compendia of safety regulatory for biomedical applications of aerogels compounds, identifying 
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List of major deliverables 
• D17: Conference and training school regarding advices and regulatory aspects on health risk, life 
cycle assessment and management on aerogel-based production and application (month 21) 
• D18: External documents and conference regarding hazard identification, exposure assessment of 
aerogel-based used in biomedical and environmental approaches (month 39) 
• D19: Recommendations on handling and exposure of aerogels for future market and post-market 
actions on aerogel-based materials used in biomedical and environmental approaches (month 45) 
• D20: Expert opinion as white paper about health risk and management on aerogel-based materials 
to be forwarded to OECD (month 48) 
3.1.2. GANTT DIAGRAM  
Month 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 
MC meeting                 
WG&CG e-meetings                 
Conferences                 
Training schools                 
STSMs                 
Web update                 
Reporting                 














The COST Action duration is set to 4 years. Management Committee (MC), Core Group (CG) and 
Working Group (WG) meetings will be carried out yearly in conjunction with COST-scientific meetings, 
except for the kick-off meeting. Meetings will be performed in the MC–CG–WG order for optimization 
of the cascade of information. Training schools will be carried out just after COST-conferences for 
optimization of resources. STSMs will already start during the first year and throughout the Action 
lifetime. A website devoted to this Action will be implemented during Q1Y1 and will be operative until 
two years after the end of the Action for the dissemination of the latest results. Scientific and financial 
reports for progress and ultimate success of the Action will be delivered during the Q4 of each year. 
3.1.3. RISK AND CONTINGENCY PLANS 
The initial consortium of the Action is believed to assemble the expertise and facilities needed to 
undergo the tasks specified in each Working Group to reach the objectives of AERoGELS Action. To 
ensure these objectives, the Chair and the MC will give a common vision about the project to all 
members, and promote a good control of quality, costs and deadlines of activities. The contingency 
plan (below) will be under the responsibility of the MC and the CG-members concerned by the risk. 
Risk description Mitigation measures Contingency plan 
Deviation in the 
initial chronogram 
Cockpit with the current 
achievements of the SMART Action 
objectives is monthly updated in the 
Intranet of the Action to follow up the 
progress and alignment with the 
Action timeframe 
Systematic examination of the deviation 
source. Once identified, the contingency 
measure will range from new 
members/events to timeline revision and 
changes in the CG-organigram. 
Scientific pitfalls 
and dead ends 
threatening a WG 
Action progresses are lively 
monitored and deviations from the 
initial objectives should be promptly 
detected 
WG-reinforcement by recruiting new 
participants and search of synergistic 
interactions by specific STSMs 
Scientific 
misconduct of a WG 
Research coordination objectives are 
evaluated each trimester by the Chair 
and the associated WG-leader 
informed 
Organization of a specific session on 
this topic within a COST event during 
the next Action year 
Difficulty to promote 
the participation of 
ECIs 
39% of the first Action consortium are 
already ECIs which should ensure a 
strong commitment of ECI’s in all 
parts and events of the Action 
If needed, STSMs/events/training 
schools will be preferentially assigned to 
ECIs and/or new young talents will be 
recruited in the consortium 
Difficulty to promote 
academia-industry 
interactions 
11 industrial partners already part of 
the Action. Organization of in-house 
workshops and BtoB meetings to 
foster interactions 
If needed, STSMs/events/training 
schools will be preferentially assigned to 
industrial partners 
 
        18 
Difficulty to reach a 
gender balance 
53% of partners are already females 
which should ensure gender balance 
in all parts and events of the Action 
If needed, STSMs/events/training 
schools/WG-leadership will be 
preferentially assigned to females  
Difficulty to organize 
training events 
All COST-members will join their 
efforts to find skilled lecturers and to 
promote high attendance 
Implementation of a call to find skilled 
experts. Search for new forums to 
announce the events  
3.2. MANAGEMENT STRUCTURES AND PROCEDURES 
The MC will be appointed to follow-up the progress and to supervise the appropriate allocation of 
funds to reach the Action objectives. MC will meet yearly in conjunction with a COST-scientific 
meeting. During these one-day meetings, the MC will decide on the approval or modification of the 
Work and Budget plans and calendar for the forthcoming scientific and networking events and mobility 
opportunities in the next time period. 
The CG will be formed by 14 members embracing the key leadership positions of the COST Action: 
Chair, Vice-Chair, 10 WG (co-)leaders, Grant holder and STSM coordinator. These roles and the 
Grant Holder Institution will be elected by the MC during the first MC-meeting. At least 4 members of 
the CG will be representatives of COST ITCs. At least 3 ECIs will be present in the CG-organigram.  
The roles of the CG-members are supplementary and cover all the expected tasks to reach the 
defined Action objectives. The Chair will be responsible for the coordination and implementation of the 
Action-activities: MC-meetings (agenda, minutes…), joint applications, work and budget plans, and 
progress and final scientific reports. The Chair should supervise the alignment of the activities with the 
objectives set in the Action MoU and periodic Work plans. The Vice-Chair will assist the Chair in the 
coordination activities and the wide dissemination of the Action’s events and activities. The Vice-Chair 
will also have a key role in the implementation of scientific events for ECIs. WG-leaders and co-
leaders are in charge of the coordination of their WG to reach the deliverables and milestones 
(Section 3.1.1) on time as well as to fulfil their specific research coordination objectives (Section 
1.2.1). The Grant holder will implement all the administrative and financial tasks linked to the Action. 
The STSM coordinator will promote and lead the organization of mobility opportunities. The STSM 
coordinator will work in close collaboration with the Vice-Chair in the drafting of the agenda of scientific 
events for ECIs to encourage interdisciplinary programs and the mentoring of transversal skills. 
Each CG-member will be responsible of the organization of a COST Action scientific meeting. The 
eligible applicants for each scientific event and activity will respect an appropriate gender balance and 
a number of ECIs of at least one third in the COST-seminars/workshops/conferences and 100% in the 
training schools. The participation of industrial partners in the events will be considered an asset of the 
Action and thus promoted, since this may catalyse networking and project initiatives based on 
innovative ideas which may lead to knowledge transfer opportunities. 
Regarding the STSMs, the selection will consider the potential for enhancement of the research 
interaction between the involved parts, measured by the impact of the exchange expected by the 
applicants. A tentative goal of 10% of STSMs to the industrial members is set. Standardized forms for 
the STSM applications and subsequent reporting/surveys will be developed by the STSM Coordinator. 
This will guarantee a uniform monitoring of the success of individual STSMs, as well as evaluation of 
the fulfilment of the participants expectations. The STSM Coordinator will proactively inform, through 
the national representatives of the participating COST countries and in the Action website, about the 
eligibility rules for the STSM applicants and the financial support rules. 
The application of ECIs (PhD students or young postdoctoral scientists) to the Action events will be 
encouraged by the STSM Coordinator, WG-leaders and Action members, considering their area of 
research and impact on their learning needs. The objective of gathering applicants contributing to 
gender balance, participation of non-COST countries and academia/industry interaction will be also 
emphasized in the exploitation plan. For visibility and a closer involvement of the ECIs in the Action 
events, a period in each event will be devoted to the dissemination of the ECIs’ scientific results (ECIs’ 
Forum) followed by their discussion with senior researchers, stimulating connections that may fruitfully 
support these ECIs in the future. Open access dissemination of results and IPR topics can also be 
discussed in these forums, taking advantage of the experiences of the senior researchers. The ECIs 
who participate in these forums may apply to the best published article of the year, being first author or 
corresponding author of the article. A prize for the best joint research collaborations within the Action 
members will award its Open Access publication in a Q1-percentile journal. The MC will select and 
announce them in the forum and these works will be highlighted in the Action website. 
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3.3. NETWORK AS A WHOLE 
The AERoGELS Action hasa consortium of researchers from internationally renowned groups. Gender 
balance criterion will be respected in the consortium and the MC during the Action lifetime. ECIs 
represent a major part of the consortium members and their participation will be boosted by the Action 
activities (STSM, forums, conferences, trainings). Participation of industry in the Action will be 
encouraged during the Action lifetime. 
The consortium embraces internationally renowned groups in the field regarding expertise and access to 
cross-cutting processing and analytical techniques, raw materials as well as end applications. All the 
sectors of the value chain are represented: raw material producers, R&D, technology providers, end 
product manufacturers and regulatory experts. Nevertheless, a foremost principle of the Action will be to 
incorporate other groups with complementary or transversal skills during the Action lifetime to broaden 
the scope and to exceed the expectations of the Action. The initial consortium embraces 3 non-COST 
Countries.•Costa Rica is a country with remarkable environmental and health indicators, as a biodiversity 
hotspot and with one of the highest rate of renewal energy production in the world. However, an alarming 
deforestation rate is a major scientific issue in the country. Costa Rica will contribute to the exchange of 
scientific knowledge in AERoGELS with the mutual benefit of a sustainable development model. •Russia 
has wide range of natural resources and is one of the fastest growing worldwide healthcare market. 
Russia is thus a top-ranked country in scientific-technological developments for environment and 
biomedical applications. The share of knowledge with Russia in AERoGELS will have a mutual benefit in 
developing aerogels for these applications. •Jordan is greatly concerned on environmental and health 
aspects with very limited water and mineral resources and a sudden increase of the population due to 
refugees. The participation of Jordan in AERoGELS will strengthen WG1&2 with the mutual benefit of 
new technologies for handling water with limited resources, and for biomedical challenges in these 
regions 
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